On July 2, Abivax S.A. rose 6.27% in pre-market trading, trading at $140.88 per share, with turnover of $425,200. The rally was driven by the completion of an upsized $800 million ADS public offering.

The company priced an underwritten public offering of 6.4 million American depositary shares at $125 each, with the offering size increased from the originally announced $600 million to $800 million, reflecting robust institutional subscription demand. Proceeds will primarily fund the commercialization of lead drug candidate obefazimod in the United States and clinical development for ulcerative colitis and Crohn's disease.

The upsizing follows the company's disclosure of positive ABTECT Maintenance Part 2 data on June 30, which showed no new safety signals and eliminated prior concerns over malignancy cases in the 50 mg group that had previously sent shares plunging nearly 50%. The stock had already rebounded over 38% on that data release. The current share price continues to trade well above the $125 offering price, underscoring sustained investor confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)